SillaJen (A215600) Stock Overview
Engages in developing technologies and products using genetic engineering in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A215600 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SillaJen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,930.00 |
| 52 Week High | ₩5,400.00 |
| 52 Week Low | ₩2,650.00 |
| Beta | 0.035 |
| 1 Month Change | -16.17% |
| 3 Month Change | -19.06% |
| 1 Year Change | -11.21% |
| 3 Year Change | -52.28% |
| 5 Year Change | n/a |
| Change since IPO | -77.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| A215600 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -11.2% | -2.0% | 6.7% |
| 1Y | -11.2% | 26.0% | 195.0% |
Return vs Industry: A215600 underperformed the KR Biotechs industry which returned 26% over the past year.
Return vs Market: A215600 underperformed the KR Market which returned 195% over the past year.
Price Volatility
| A215600 volatility | |
|---|---|
| A215600 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A215600 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A215600's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 57 | Jaekyung Kim | www.sillajen.com |
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial.
SillaJen, Inc. Fundamentals Summary
| A215600 fundamental statistics | |
|---|---|
| Market cap | ₩405.96b |
| Earnings (TTM) | -₩24.13b |
| Revenue (TTM) | ₩10.92b |
Is A215600 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A215600 income statement (TTM) | |
|---|---|
| Revenue | ₩10.92b |
| Cost of Revenue | ₩3.94b |
| Gross Profit | ₩6.98b |
| Other Expenses | ₩31.11b |
| Earnings | -₩24.13b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -174.16 |
| Gross Margin | 63.95% |
| Net Profit Margin | -220.98% |
| Debt/Equity Ratio | 0.7% |
How did A215600 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 03:36 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SillaJen, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wan Ku | NH Investment & Securities Co., Ltd. |
| Kidal Bae | Shinhan Investment Corp. |